SCOPUS 정보 검색 플랫폼

Volumn 139, Issue 2, 2019, Pages 152-154

Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus: Lost in Translation Between Clinical Trial Design, Regulatory Standards, and Practice Guidelines

(2) Greene, Stephen J a,b Butler, Javed c

a DUKE CLINICAL RESEARCH INSTITUTE (United States)

b DUKE UNIVERSITY SCHOOL OF MEDICINE (United States)

c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE (United States)

Author keywords

cardiovascular diseases; diabetes mellitus, type 2; guideline; heart failure; outcome assessment (health care); sodium glucose transport proteins

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CANAGLIFLOZIN; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COMORBIDITY; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK MANAGEMENT; ADVERSE EVENT; BLOOD; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; PROTECTION; RISK ASSESSMENT;

BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85059928489 PISSN: 00097322 EISSN: 15244539 Source Type: Journal
DOI: 10.1161/CIRCULATIONAHA.118.037599 Document Type: Review

Times cited : (18)

References (5)

1
- 85051826396
- Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes
- Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjörnsdottir S. Risk Factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633-644. doi: 10.1056/NEJMoa1800256
- (2018) N Engl J Med. , vol.379 , pp. 633-644
- Rawshani, A.¹ Rawshani, A.² Franzén, S.³ Sattar, N.⁴ Eliasson, B.⁵ Svensson, A.M.⁶ Zethelius, B.⁷ Miftaraj, M.⁸ McGuire, D.K.⁹ Rosengren, A.¹⁰ Gudbjörnsdottir, S.¹¹

2
- 85026905959
- 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/ American Heart Association Task Force on clinical practice guidelines and the heart failure society of America
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137-e161. doi: 10.1161/CIR.0000000000000509
- (2017) Circulation. , vol.136 , pp. e137-e161
- Yancy, C.W.¹ Jessup, M.² Bozkurt, B.³ Butler, J.⁴ Casey, D.E.⁵ Colvin, M.M.⁶ Drazner, M.H.⁷ Filippatos, G.S.⁸ Fonarow, G.C.⁹ Givertz, M.M.¹⁰ Hollenberg, S.M.¹¹ Lindenfeld, J.¹² Masoudi, F.A.¹³ McBride, P.E.¹⁴ Peterson, P.N.¹⁵ Stevenson, L.W.¹⁶ Westlake, C.¹⁷

3
- 84944800184
- Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
- EMPA-REG OUTCOME Investigators
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720
- (2015) N Engl J Med. , vol.373 , pp. 2117-2128
- Zinman, B.¹ Wanner, C.² Lachin, J.M.³ Fitchett, D.⁴ Bluhmki, E.⁵ Hantel, S.⁶ Mattheus, M.⁷ Devins, T.⁸ Johansen, O.E.⁹ Woerle, H.J.¹⁰ Broedl, U.C.¹¹ Inzucchi, S.E.¹²

4
- 85023777061
- Canagliflozin and cardiovascular and renal events in type 2 diabetes
- CANVAS Program Collaborative Group
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. doi: 10.1056/NEJMoa1611925
- (2017) N Engl J Med. , vol.377 , pp. 644-657
- Neal, B.¹ Perkovic, V.² Mahaffey, K.W.³ De Zeeuw, D.⁴ Fulcher, G.⁵ Erondu, N.⁶ Shaw, W.⁷ Law, G.⁸ Desai, M.⁹ Matthews, D.R.¹⁰

5
- 85019731757
- Lower risk of heart failure and death in patients initiated on sodiumglucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL Study (Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)
- CVD-REAL Investigators and Study Group
- Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodiumglucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136:249-259. doi: 10.1161/CIRCULATIONAHA. 117.029190
- (2017) Circulation. , vol.136 , pp. 249-259
- Kosiborod, M.¹ Cavender, M.A.² Fu, A.Z.³ Wilding, J.P.⁴ Khunti, K.⁵ Holl, R.W.⁶ Norhammar, A.⁷ Birkeland, K.I.⁸ Jørgensen, M.E.⁹ Thuresson, M.¹⁰ Arya, N.¹¹ Bodegård, J.¹² Hammar, N.¹³ Fenici, P.¹⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.